Top 20 can­cer drug deals: As­traZeneca just changed the glob­al land­scape for deal­mak­ing in on­col­o­gy

As­traZeneca CEO Pas­cal So­ri­ot has been one of the most cau­tious Big Phar­ma CEOs in the busi­ness — un­til Thurs­day. He had to be. Af­ter be­ing hand­ed com­mand of a leaky ship sail­ing shark in­fest­ed wa­ters, So­ri­ot’s As­traZeneca be­came known for (a) dogged per­sis­tence in pur­su­ing its big new can­cer drug fran­chis­es (b) a bad pen­chant for key tri­al fail­ures and (c) care­ful­ly aligned as­set sales to keep the num­bers in tune for Wall Street.

In many ways, the com­pa­ny’s em­bar­rass­ing odyssey try­ing to com­plete a new world head­quar­ters in Cam­bridge UK sum­ma­rized things com­plete­ly: Off bud­get, way be­hind sched­ule and ex­treme­ly am­bi­tious. It would be beau­ti­ful, if there weren’t so many prob­lems.

Then, in one swoop, So­ri­ot changed tack com­plete­ly. In place of cau­tion and en­durance, So­ri­ot went big, hand­ing his new can­cer drug R&D chief José Basel­ga a ma­jor role for a Phase III can­cer drug with sig­nif­i­cant near-term reg­u­la­to­ry cat­a­lysts. And while you may not have heard a lot about this drug, As­traZeneca clear­ly be­lieves it has one of the next big things in the on­col­o­gy drug field.

We asked Chris Doko­ma­ji­lar at Deal­For­ma to run the num­bers for us, and he came up with the top 10 deals that As­traZeneca has done and how this new pact with Dai­ichi Sankyo lines up among the top 20 can­cer drug deals of the past decade.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER